Update on iron supplementation in patients with cancer-related anemia.
Study Goal
The researchers aimed to evaluate the efficacy and safety of IV iron for treating cancer-related anemia (CRA) and to address barriers to its utilization.
Results Summary
The study found that IV iron is highly effective and safe for treating CRA, with overwhelming positive clinical trial data, yet it remains underutilized due to unfounded safety concerns and lack of physician awareness. Poor patient quality of life and exposure to riskier anemia treatments persist as a result.
Population
Patients with cancer-related anemia (CRA).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
IV iron | neutral | cancer-related anemia (CRA) | - | - | affirm the efficacy and safety | #1 |
IV iron | no change | cancer-related anemia (CRA) | - | - | remains underutilized | #2 |
IV iron | decrease | patient quality of life | patients | - | leads to poor patient quality of life | #3 |
IV iron | increase | safety risks | patients | - | patient exposure to anemia treatments that have greater safety risks | #4 |
new oral iron therapy products | neutral | treatment of CRA | - | - | has the potential to dramatically simplify | #5 |
new oral iron therapy products | neutral | anemia of inflammation | - | - | effective in treating | #6 |
INTRODUCTION: Numerous clinical trials affirm the efficacy and safety of IV iron to treat cancer-related anemia (CRA). Nonetheless, evaluation and treatment of CRA remains suboptimal. AREAS COVERED: This review summarizes CRA therapy with a focus on iron deficiency and its treatment. The literature search was conducted using the National Library of Medicine (PubMed) database from 2004 to 2024. Topics reviewed include CRA pathophysiology, laboratory diagnosis of iron deficiency, a summary of clinical trial results using IV iron to treat CRA, and safety aspects. EXPERT OPINION: Despite overwhelming positive efficacy and safety data, IV iron remains underutilized to treat CRA. This is likely due to persistent (unfounded) concerns about IV iron safety and lack of physician awareness of newer clinical trial data. This leads to poor patient quality of life and patient exposure to anemia treatments that have greater safety risks than IV iron. Solutions to this problem include increased educational efforts and considering alternative treatment models in which other providers separately manage CRA. The recent availability of new oral iron therapy products that are effective in treating anemia of inflammation has the potential to dramatically simplify the treatment of CRA.